title: rhGM-CSF vs placebo following rhGM-CSF-mobilized PBPC transplantation: a phase III double-blind randomized trial.
abstract: In this placebo-controlled randomized trial we evaluated the hematological and clinical effects of r-Hu GM-CSF after high-dose chemotherapy (HDC) followed by GM-CSF-mobilized PBPC transplantation. Fifty patients with poor prognosis malignancies were randomized in a double-blind study to receive either GM-CSF or placebo after HDC followed by PBPC rescue. For all patients, PBPCs were recruited using a combination of VP-16 (300 mg/m2 on days 1 and 2), cytoxan (3 g/m2 on days 3 and 4) and GM-CSF (5 micrograms/kg from day 5). No differences were demonstrated between the two groups in median time to neutrophil or platelet recoveries. There was no significant difference between the GM-CSF group and the placebo group in the median duration of post-transplant hospitalization, in the number of days of antibiotic treatment, in the number of infections and in red blood cell or platelet transfusion requirements. There was a significant difference with an advantage for the placebo group in the mean duration of febrile days (P = 0.01). We conclude that the administration of GM-CSF in patients transplanted with GM-CSF-mobilized PBPC is not associated with a clinical benefit in term of tempo of engraftment, numbers of documented infections, transfusion requirements and mucositis grading.
authors.affiliation: Centre Jean Perrin, Clermont-Ferrand, France.
authors.forename: M
authors.initials: M
authors.lastname: Legros
authors.forename: J
authors.initials: J
authors.lastname: Fleury
authors.forename: J O
authors.initials: JO
authors.lastname: Bay
authors.forename: B
authors.initials: B
authors.lastname: Choufi
authors.forename: M
authors.initials: M
authors.lastname: Basile
authors.forename: P
authors.initials: P
authors.lastname: Condat
authors.forename: C
authors.initials: C
authors.lastname: Glenat
authors.forename: Y
authors.initials: Y
authors.lastname: Communal
authors.forename: F
authors.initials: F
authors.lastname: Tavernier
authors.forename: J M
authors.initials: JM
authors.lastname: Bons
authors.forename: P
authors.initials: P
authors.lastname: Chollet
authors.forename: R
authors.initials: R
authors.lastname: Plagne
authors.forename: J
authors.initials: J
authors.lastname: Chassagne
mesh_terms: D000328:Adult; D002454:Cell Differentiation; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy; D011994:Recombinant Proteins / Q000008:administration & dosage; D014182:Transplantation, Autologous
chemical_list: D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor